PB103 NK Cells

· Precision Biotech Taiwan Corp.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PB103 NK Cells, covering 2025-02-14 to 2025-02-14. Get the full timeline:

Most recent: Clinical Trial Update: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients [Phase 1, Phase 2]